Naveris is a privately held, commercial-stage oncology diagnostic company with facilities in both MA and NC. They aim to transform cancer detection through minimally invasive liquid biopsies. Their research revolves around circulating tumor-tissue modified viral DNA (TTMV-DNA) blood tests. This test offers highly sensitive and specific early detection of cancers up to months before symptoms appear. NavDx is a blood test for personalized care of people with HPV-positive head, neck, or anal cancer. Naveris’ blood tests can also assist in monitoring treatment response and disease recurrence, improving patient outcomes. Naveris is investigating the potential of TTMV-DNA for applications in other cancer types beyond HPV-driven cancers.

Naveris

Founded: 2017
Location: Natick, MA
Employee range: 11 - 50
Funding: $33.4M A Sep 2022; $19M Dec 2020
Investors: Gurnet Point Capital, TechU Ventures, BrightEdge, the impact and venture capital arm of the American Cancer Society

About:

Jobs: